PL
PCVX icon

Parkwood LLC’s Vaxcyte PCVX Stock Holding History

Parkwood LLC’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,702
Closed -$884K – 120
2024
Q2 		$884K Sell
11,702
-1,853
-14% -$126K 0.11% 95
2024
Q1 		$926K Sell
13,555
-1,925
-12% -$133K 0.08% 148
2023
Q4 		$972K Sell
15,480
-1,161
-7% -$60.3K 0.12% 94
2023
Q3 		$848K Buy
16,641
+1,863
+13% +$91.9K 0.09% 92
2023
Q2 		$738K Sell
14,778
-2,177
-13% -$103K 0.13% 94
2023
Q1 		$635K Buy
16,955
+9,637
+132% +$409K 0.09% 109
2022
Q4 		$351K Sell
7,318
-4,940
-40% -$194K 0.05% 124
2022
Q3 		$294K Buy
12,258
+348
+3% +$8.82K 0.04% 130
2022
Q2 		$259K Buy
+11,910
New +$276K 0.05% 127
2021
Q1 		– Sell
-28,191
Closed -$749K – 129
2020
Q4 		$749K Buy
+28,191
New +$1.05M 0.09% 97

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parkwood LLC's PCVX Position: Q3 2024 in Review

Parkwood LLC sold out of Vaxcyte (PCVX) in Q3 2024, closing a stake of 11,702 shares — an estimated $884K sold.

Parkwood LLC first reported a position in PCVX in Q4 2020 and held it in 10 quarters. The position peaked at $972K in Q4 2023. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

  • Parkwood LLC reported no remaining Vaxcyte position as of Q3 2024 after selling out during the quarter.
  • Parkwood LLC sold 11,702 Vaxcyte shares in Q3 2024, an estimated $884K.
  • Parkwood LLC first reported a position in Vaxcyte in Q4 2020 and held it in 10 quarters.
  • Parkwood LLC's Vaxcyte position peaked at $972K in Q4 2023.
  • 328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on Parkwood LLC's 13F filing for Q3 2024, filed 14 Nov 2024.